Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006453 · ClinicalTrials.gov registry record · Phase 3

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

A Phase 3 study, sponsored by AGO Study Group.

Completed
Registry status
Phase 3
Development phase

NCT00006453: Completed Phase 3 study, sponsored by AGO Study Group.

NCT00006453 is a Phase 3 study that has completed, run by AGO Study Group. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006453, a Phase 3 study, has completed, sponsored by AGO Study Group.

COMPLETED
Registry status
Phase 3
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without gemcitabine for ovarian epithelial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin with or without gemcitabine in treating patients who have advanced ovarian epithelial cancer that has not responded to previous chemotherapy.

Interventions

  • DRUG carboplatin
  • DRUG gemcitabine hydrochloride

Trial Details

FieldValue
Start Date 1999-09
Est. Completion 2006-10
Phase Phase 3
AGO Study Group

2 total trials

What the finished NCT00006453 record still lists

NCT00006453 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.

NCT00006453 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00006453 about?

NCT00006453 is a clinical study titled "Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without gemcitabine for ovarian epithelial cancer. PURPOSE: Ra...

What is the current status of trial NCT00006453?

This trial is currently completed. It is a Phase 3 study. The study started on 1999-09. Estimated completion is 2006-10.

What interventions are being tested in trial NCT00006453?

The interventions under investigation include: carboplatin (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00006453?

This trial is sponsored by AGO Study Group, which has 2 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00006453, the US trial registry maintained by the National Library of Medicine. NCT00006453 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.